CCT6A Facilitates Lung Adenocarcinoma Progression and Glycolysis Via STAT1/HK2 Axis

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2024 May 15

PMID 38750462

Authors

Shao-Kun Yu

Tao Yu

Yu-Ming Wang

Ao Sun

Jia Liu

Kai-Hua Lu

Affiliations

Soon will be listed here.

Abstract

Background: Chaperonin Containing TCP1 Subunit 6 A (CCT6A) is a prominent protein involved in the folding and stabilization of newly synthesized proteins. However, its roles and underlying mechanisms in lung adenocarcinoma (LUAD), one of the most aggressive cancers, remain elusive.

Methods: Our study utilized in vitro cell phenotype experiments to assess CCT6A's impact on the proliferation and invasion capabilities of LUAD cell lines. To delve into CCT6A's intrinsic mechanisms affecting glycolysis and proliferation in lung adenocarcinoma, we employed transcriptomic sequencing and liquid chromatography-mass spectrometry analysis. Co-immunoprecipitation (Co-IP) and chromatin immunoprecipitation (CHIP) assays were also conducted to substantiate the mechanism.

Results: CCT6A was found to be significantly overexpressed in LUAD and associated with a poorer prognosis. The silencing of CCT6A inhibited the proliferation and migration of LUAD cells and elevated apoptosis rates. Mechanistically, CCT6A interacted with STAT1 protein, forming a complex that enhances the stability of STAT1 by protecting it from ubiquitin-mediated degradation. This, in turn, facilitated the transcription of hexokinase 2 (HK2), a critical enzyme in aerobic glycolysis, thereby stimulating LUAD's aerobic glycolysis and progression.

Conclusion: Our findings reveal that the CCT6A/STAT1/HK2 axis orchestrated a reprogramming of glucose metabolism and thus promoted LUAD progression. These insights position CCT6A as a promising candidate for therapeutic intervention in LUAD treatment.

Citing Articles

Enhanced Antitumor Activity of Korean Black Soybean Cultivar 'Soman' by Targeting STAT-Mediated Aerobic Glycolysis.

Park S, Seo J, Kim M, Yun H, Kang B, Kim J Antioxidants (Basel). 2025; 14(2).

PMID: 40002413 PMC: 11852074. DOI: 10.3390/antiox14020228.

[Construction and Validation of A Prognostic Model for Lung Adenocarcinoma  Based on Ferroptosis-related Genes].

Zhang Z, Zhao W, Hu Z, Ding C, Huang H, Liang G Zhongguo Fei Ai Za Zhi. 2025; 28(1):22-32.

PMID: 39988436 PMC: 11848621. DOI: 10.3779/j.issn.1009-3419.2025.102.04.

Integration of single-cell and bulk RNA sequencing to identify a distinct tumor stem cells and construct a novel prognostic signature for evaluating prognosis and immunotherapy in LUAD.

Zhao F, Chen M, Wu T, Ji M, Li F J Transl Med. 2025; 23(1):222.

PMID: 39987127 PMC: 11847374. DOI: 10.1186/s12967-025-06243-6.

A method for the identification of lactate metabolism-related prognostic biomarkers and its validations in non-small cell lung cancer.

Yang W, Gu M, Zhang Y, Zhang Y, Liu T, Wu D Sci Rep. 2025; 15(1):5812.

PMID: 39962075 PMC: 11832748. DOI: 10.1038/s41598-025-85620-z.

Metabolic reprogramming in lung cancer and its clinical implication.

Huang Q, Fan L, Gong M, Ren J, Chen C, Xie S Front Pharmacol. 2025; 15:1516650.

PMID: 39744129 PMC: 11688361. DOI: 10.3389/fphar.2024.1516650.

References

Ma X, Lu C, Chen Y, Li S, Ma N, Tao X . CCT2 is an aggrephagy receptor for clearance of solid protein aggregates. Cell. 2022; 185(8):1325-1345.e22. DOI: 10.1016/j.cell.2022.03.005. View

Llorca O, Martin-Benito J, Grantham J, Hynes G, Willison K, Carrascosa J . Eukaryotic chaperonin CCT stabilizes actin and tubulin folding intermediates in open quasi-native conformations. EMBO J. 2000; 19(22):5971-9. PMC: 305829. DOI: 10.1093/emboj/19.22.5971. View

Liu Y, Zhang X, Lin J, Chen Y, Qiao Y, Guo S . CCT3 acts upstream of YAP and TFCP2 as a potential target and tumour biomarker in liver cancer. Cell Death Dis. 2019; 10(9):644. PMC: 6733791. DOI: 10.1038/s41419-019-1894-5. View

Kaganoi J, Watanabe G, Okabe M, Nagatani S, Kawabe A, Shimada Y . STAT1 activation-induced apoptosis of esophageal squamous cell carcinoma cells in vivo. Ann Surg Oncol. 2007; 14(4):1405-15. DOI: 10.1245/s10434-006-9274-7. View

Zhang L, Li Q, Yang J, Xu P, Xuan Z, Xu J . Cytosolic TGM2 promotes malignant progression in gastric cancer by suppressing the TRIM21-mediated ubiquitination/degradation of STAT1 in a GTP binding-dependent modality. Cancer Commun (Lond). 2022; 43(1):123-149. PMC: 9859732. DOI: 10.1002/cac2.12386. View

Pordel S, Khorrami M, Saadatpour F, Rezaee D, Cho W, Jahani S . The role of microRNA-185 in the pathogenesis of human diseases: A focus on cancer. Pathol Res Pract. 2023; 249:154729. DOI: 10.1016/j.prp.2023.154729. View

Li W, Liu J, Zhao H . Prognostic Power of a Chaperonin Containing TCP-1 Subunit Genes Panel for Hepatocellular Carcinoma. Front Genet. 2021; 12:668871. PMC: 8061729. DOI: 10.3389/fgene.2021.668871. View

Khodarev N, Ahmad R, Rajabi H, Pitroda S, Kufe T, McClary C . Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene. 2009; 29(6):920-9. PMC: 2820589. DOI: 10.1038/onc.2009.391. View

Wang D, Zhao C, Xu F, Zhang A, Jin M, Zhang K . Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2. Theranostics. 2021; 11(6):2860-2875. PMC: 7806469. DOI: 10.7150/thno.51797. View

10.

Gong L, Cui Z, Chen P, Han H, Peng J, Leng X . Reduced survival of patients with hepatocellular carcinoma expressing hexokinase II. Med Oncol. 2011; 29(2):909-14. DOI: 10.1007/s12032-011-9841-z. View

11.

Liu R, Li Y, Tian L, Shi H, Wang J, Liang Y . Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating β-catenin/c-Myc signaling in human hepatocellular carcinoma. Cancer Lett. 2018; 443:34-46. DOI: 10.1016/j.canlet.2018.11.030. View

12.

Cao L, Wang M, Dong Y, Xu B, Chen J, Ding Y . Circular RNA circRNF20 promotes breast cancer tumorigenesis and Warburg effect through miR-487a/HIF-1α/HK2. Cell Death Dis. 2020; 11(2):145. PMC: 7039970. DOI: 10.1038/s41419-020-2336-0. View

13.

Lunt S, Vander Heiden M . Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011; 27:441-64. DOI: 10.1146/annurev-cellbio-092910-154237. View

14.

Zeng Y, Chen H, Zhang Z, Fan J, Li J, Zhou S . IFI44L as a novel epigenetic silencing tumor suppressor promotes apoptosis through JAK/STAT1 pathway during lung carcinogenesis. Environ Pollut. 2022; 319:120943. DOI: 10.1016/j.envpol.2022.120943. View

15.

Xia Y, Wang X, Liu Y, Shapiro E, Lepor H, Tang M . PKM2 Is Essential for Bladder Cancer Growth and Maintenance. Cancer Res. 2021; 82(4):571-585. PMC: 8857058. DOI: 10.1158/0008-5472.CAN-21-0403. View

16.

Hartl F, Martin J . Molecular chaperones in cellular protein folding. Curr Opin Struct Biol. 1995; 5(1):92-102. DOI: 10.1016/0959-440x(95)80014-r. View

17.

Zong S, Jiao Y, Liu X, Mu W, Yuan X, Qu Y . FKBP4 integrates FKBP4/Hsp90/IKK with FKBP4/Hsp70/RelA complex to promote lung adenocarcinoma progression via IKK/NF-κB signaling. Cell Death Dis. 2021; 12(6):602. PMC: 8192522. DOI: 10.1038/s41419-021-03857-8. View

18.

Wang J, Huang Q, Hu X, Zhang S, Jiang Y, Yao G . Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer. Cancer Res. 2022; 82(8):1503-1517. PMC: 9662874. DOI: 10.1158/0008-5472.CAN-21-1820. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Xu S, Herschman H . A Tumor Agnostic Therapeutic Strategy for Hexokinase 1-Null/Hexokinase 2-Positive Cancers. Cancer Res. 2019; 79(23):5907-5914. DOI: 10.1158/0008-5472.CAN-19-1789. View